Mizuho Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Pediatrix Medical Group (NYSE:MD) had its price target upped by equities researchers at Mizuho from $13.00 to $15.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential downside of 2.34% from the stock’s previous close.

MD has been the subject of a number of other reports. Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their price objective for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. UBS Group upped their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research report on Friday, August 9th. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Truist Financial upped their price objective on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Trading Up 1.5 %

MD stock opened at $15.36 on Monday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -5.02, a PEG ratio of 2.36 and a beta of 1.55. The company has a quick ratio of 1.38, a current ratio of 1.58 and a debt-to-equity ratio of 0.86. The business has a fifty day simple moving average of $11.70 and a 200-day simple moving average of $9.45. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $15.52.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period in the prior year, the firm earned $0.29 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares in the company, valued at $1,943,272.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO C Marc Richards sold 32,562 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares in the company, valued at $1,943,272.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,100 shares of company stock valued at $701,889. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Several large investors have recently made changes to their positions in the company. Atria Investments Inc increased its stake in shares of Pediatrix Medical Group by 9.0% in the third quarter. Atria Investments Inc now owns 27,124 shares of the company’s stock valued at $314,000 after purchasing an additional 2,238 shares during the period. Principal Financial Group Inc. grew its position in Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after buying an additional 63,581 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Pediatrix Medical Group by 352.4% in the third quarter. Nisa Investment Advisors LLC now owns 21,513 shares of the company’s stock worth $249,000 after buying an additional 16,758 shares during the last quarter. Everence Capital Management Inc. acquired a new position in Pediatrix Medical Group in the third quarter worth approximately $149,000. Finally, Creative Planning grew its position in Pediatrix Medical Group by 48.3% during the 3rd quarter. Creative Planning now owns 30,662 shares of the company’s stock worth $355,000 after purchasing an additional 9,991 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.